Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
4.850
+0.090 (1.89%)
Jun 24, 2025, 4:00 PM - Market closed
Dogwood Therapeutics Employees
Dogwood Therapeutics had 12 employees as of December 31, 2024. The number of employees increased by 8 or 200.00% compared to the previous year.
Employees
12
Change (1Y)
8
Growth (1Y)
200.00%
Revenue / Employee
n/a
Profits / Employee
-$1,979,509
Market Cap
9.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
DWTX News
- 21 days ago - Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference - GlobeNewsWire
- 6 weeks ago - Dogwood Therapeutics Announces First Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - Newsfile Corp
- 2 months ago - Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewsWire
- 2 months ago - Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewsWire
- 3 months ago - Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain - GlobeNewsWire
- 3 months ago - Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire